A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons
- PMID: 16838232
- DOI: 10.1086/505868
A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons
Abstract
Background: To compare the effectiveness of oseltamivir for treatment of influenza A and influenza B, we conducted a prospective, multicenter study of the 2003-2004 and 2004-2005 influenza seasons. The study included 3351 patients in whom influenza had been diagnosed by use of an antigen detection test kit.
Methods: Oseltamivir was administered to 1818 patients with influenza A and 1485 patients with influenza B. No anti-influenza drugs were administered to 21 patients with influenza A or to 27 patients with influenza B. Patients receiving oseltamivir therapy were divided into 4 groups according to the time between the onset of fever (temperature, > or = 37.5 degrees C) and administration of the first dose of oseltamivir (0-12 h, 13-24 h, 25-36 h, and 37-48 h). The patients were also divided into 4 subgroups on the basis of age (0-6 years, 7-15 years, 16-64 years, and >64 years). Virus isolation was performed after completion of oseltamivir therapy for 44 patients with influenza A and 31 patients with influenza B.
Results: The duration of fever was significantly shorter for patients with influenza A and B who were treated with oseltamivir than for patients who were not treated with an anti-influenza drug (P<.001 for both). The time until the patient became afebrile after the initial administration of oseltamivir and the duration of fever were significantly longer for patients with influenza B than for patients with influenza A for the 0-12 h, 13-24 h, 25-36 h, and 37-48 h groups (P<.001) and for all age groups (P<.001). After 4-6 days of oseltamivir therapy, the influenza B virus reisolation rate (51.6%) was significantly higher than the influenza A virus reisolation rate (15.9%) (P<.001).
Conclusion: Oseltamivir is less effective for influenza B than for influenza A with regard to duration of fever and virus persistence, irrespective of patient age or the timing of administration of the first dose.
Comment in
-
Oseltamivir and the influenza alphabet.Clin Infect Dis. 2006 Aug 15;43(4):445-6. doi: 10.1086/505873. Epub 2006 Jun 26. Clin Infect Dis. 2006. PMID: 16838233 No abstract available.
Similar articles
-
Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.Clin Infect Dis. 2005 May 1;40(9):1309-16. doi: 10.1086/429241. Epub 2005 Mar 16. Clin Infect Dis. 2005. PMID: 15825034
-
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.J Infect. 2008 Jan;56(1):51-7. doi: 10.1016/j.jinf.2007.09.002. Epub 2007 Oct 15. J Infect. 2008. PMID: 17936910 Clinical Trial.
-
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.Clin Infect Dis. 2009 Dec 15;49(12):1828-35. doi: 10.1086/648424. Clin Infect Dis. 2009. PMID: 19911968
-
Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.Med Microbiol Immunol. 2002 Dec;191(3-4):165-8. doi: 10.1007/s00430-002-0139-9. Epub 2002 Sep 12. Med Microbiol Immunol. 2002. PMID: 12458353 Review.
-
Oseltamivir for influenza.Drug Ther Bull. 2002 Dec;40(12):89-91. Drug Ther Bull. 2002. PMID: 12613182 Review.
Cited by
-
Serum High-Mobility-Group Box 1 as a Biomarker and a Therapeutic Target during Respiratory Virus Infections.mBio. 2018 Mar 13;9(2):e00246-18. doi: 10.1128/mBio.00246-18. mBio. 2018. PMID: 29535197 Free PMC article.
-
Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.Sci Rep. 2017 Aug 4;7(1):7345. doi: 10.1038/s41598-017-07433-z. Sci Rep. 2017. PMID: 28779075 Free PMC article.
-
Antiviral treatment for viral pneumonia: current drugs and natural compounds.Virol J. 2025 Mar 6;22(1):62. doi: 10.1186/s12985-025-02666-1. Virol J. 2025. PMID: 40050867 Free PMC article. Review.
-
Influenza B presenting with bicytopenia in an adult - An unusual presentation and failure of antimicrobial stewardship by a practicing physician.J Family Med Prim Care. 2020 Jul 30;9(7):3737-3740. doi: 10.4103/jfmpc.jfmpc_711_20. eCollection 2020 Jul. J Family Med Prim Care. 2020. PMID: 33102360 Free PMC article.
-
Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.J Antimicrob Chemother. 2019 May 1;74(5):1333-1341. doi: 10.1093/jac/dky560. J Antimicrob Chemother. 2019. PMID: 30715325 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical